This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |
| conjunctival_pigmented_lesions [2026/02/25 19:43] – Scott Larson | conjunctival_pigmented_lesions [2026/02/25 19:50] (current) – Scott Larson |
|---|
| * For diffuse disease or tarsal conjunctiva | * For diffuse disease or tarsal conjunctiva |
| * Cryotherapy with double freeze-thaw | * Cryotherapy with double freeze-thaw |
| | * Topical interferon alpha-2b |
| * Topical mytomycin C 0.02% or 0.04% | * Topical mytomycin C 0.02% or 0.04% |
| * QID x 1 week | * QID x 1 week |
| - [[https://www.aao.org/eyenet/article/conjunctival-pigmented-lesions-diagnosis-managemen |Conjunctival Pigmented Lesions: Diagnosis and Management. Sayaad FFE et al. Eyenet September 2013]] | - [[https://www.aao.org/eyenet/article/conjunctival-pigmented-lesions-diagnosis-managemen |Conjunctival Pigmented Lesions: Diagnosis and Management. Sayaad FFE et al. Eyenet September 2013]] |
| - [[https://pubmed.ncbi.nlm.nih.gov/14711437/ |Tumors of the conjunctiva and cornea. Shields CL, Shields JA. Surv Ophthalmol. 2004;49(1):3-24]] | - [[https://pubmed.ncbi.nlm.nih.gov/14711437/ |Tumors of the conjunctiva and cornea. Shields CL, Shields JA. Surv Ophthalmol. 2004;49(1):3-24]] |
| | - [[https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S003962572200039X?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS003962572200039X%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F| Use of interferon alpha 2b to manage primary acquired melanosis and conjunctival melanoma. Cid-Bertomeu P, et al. Surv Ophthalmol. 2022;67(5):1391-1404]] |